Nonmelanoma Skin Cancer Epidemiology Forecast 2025-2034

Nonmelanoma skin cancer (NMSC) is the most common type of skin cancer, primarily affecting the basal and squamous cells. It is often linked to excessive sun exposure and can lead to disfigurement if untreated. Nonmelanoma skin cancer has a high survival rate, but early detection is crucial. In the UK, the incidence is expected to rise by 14% from 2023-2025 to 2038-2040, reflecting increasing sun exposure and ageing populations.

Nonmelanoma Skin Cancer Epidemiology Forecast Report Coverage

The “Nonmelanoma Skin Cancer Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of nonmelanoma skin cancer. It projects the future incidence and prevalence rates of nonmelanoma skin cancer across various populations. The study covers age, gender, and type as major determinants of the nonmelanoma skin cancer-affected population. The report highlights patterns in the prevalence of nonmelanoma skin cancer over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of nonmelanoma skin cancer in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Nonmelanoma Skin Cancer Disease Overview

Nonmelanoma skin cancer refers to a group of skin cancers that develop in the outer layers of the skin. The most common types are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). These cancers are typically caused by long-term exposure to ultraviolet (UV) radiation, often from sunlight. Nonmelanoma skin cancer usually presents as growths or sores on the skin that may bleed, crust, or not heal. While it rarely spreads to other parts of the body, early detection and treatment are essential to prevent further complications.

Nonmelanoma Skin Cancer: Treatment Overview

Nonmelanoma skin cancer treatment aims to remove or destroy cancerous cells while preserving surrounding healthy tissue. Common treatments include surgical excision, where the tumour is cut out, and Mohs surgery, a precise technique to remove cancer layer by layer. Cryotherapy involves freezing the tumour, while topical treatments like chemotherapy creams can target surface-level cancers. Radiation therapy may be used for tumours in hard-to-reach areas, and photodynamic therapy uses light-sensitive drugs to treat cancer. The choice of treatment depends on the tumour's size, location, and stage.

Epidemiology

The nonmelanoma skin cancer epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for nonmelanoma skin cancer by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for nonmelanoma skin cancer and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• In 2022, non-melanoma skin cancer was the fifth most common cancer globally, with an incidence of 1,234,533 cases.
• North America and Asia recorded the highest incidence and mortality rates for non-melanoma skin cancers.
• Approximately 5.4 million basal and squamous cell skin cancers are diagnosed annually in the United States, affecting about 3.3 million people.
• Basal cell carcinoma (BCC) accounts for around 80% of cases, while squamous cell carcinoma (SCC) is less common.
• Despite their high prevalence, mortality rates are low. Estimated deaths in the United States range from 2,000 to 8,000 per year, with most due to squamous cell carcinoma.

Country-wise Nonmelanoma Skin Cancer Epidemiology

The nonmelanoma skin cancer epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Nonmelanoma skin cancer is a significant global health concern, with varying incidence rates across regions. In the United States, around 90% of the cases are linked to ultraviolet (UV) radiation exposure from the sun. Moreover, around 5,400 people die from skin cancer evry month. Countries like Japan, influenced by lifestyle factors and increased sun exposure also experience significant cases. In Europe, incidence rates are moderate. These regional variations highlight the impact of environmental and genetic factors on skin cancer prevalence.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of nonmelanoma skin cancer based on several factors.
• Nonmelanoma Skin Cancer Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of nonmelanoma skin cancer are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of nonmelanoma skin cancer epidemiology in the 8 major markets?
• What will be the total number of patients with nonmelanoma skin cancer across the 8 major markets during the forecast period?
• What was the country-wise prevalence of nonmelanoma skin cancer in the 8 major markets in the historical period?
• Which country will have the highest number of nonmelanoma skin cancer patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of nonmelanoma skin cancer during the forecast period of 2025-2034?
• What are the currently available treatments for nonmelanoma skin cancer?
• What are the disease risks, signs, symptoms, and unmet needs of nonmelanoma skin cancer?

This product will be delivered within 3-5 business days.